• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Licensing fees boost Sonus’ Q4 profits

Article

Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into

Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into a $10 million patent cross-licensing agreement with Nycomed last September (SCAN 10/13/99). That agreement helped Sonus’ year-end results considerably as well; the company reported revenues of $12 million for 1999, compared to $5 million in 1998. Net income for the year was $400,000, compared to a net loss of $11.2 million for 1998. Sonus is currently awaiting FDA clearance for EchoGen, its first ultrasound contrast agent, which the company already sells in Europe.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.